DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,276,076 | -2.1% | 45,450 | -5.3% | 0.89% | +3.1% |
| Q2 2023 | $11,517,181 | -1.2% | 47,988 | +3.8% | 0.87% | -6.8% |
| Q1 2023 | $11,652,696 | -2.8% | 46,234 | +2.3% | 0.93% | -6.1% |
| Q4 2022 | $11,994,472 | +5.5% | 45,191 | +2.6% | 0.99% | -4.7% |
| Q3 2022 | $11,372,000 | +3.3% | 44,027 | +1.3% | 1.04% | +8.9% |
| Q2 2022 | $11,013,000 | -12.0% | 43,441 | +1.8% | 0.95% | +2.4% |
| Q1 2022 | $12,514,000 | -6.9% | 42,663 | +4.5% | 0.93% | +2.4% |
| Q4 2021 | $13,435,000 | +10.9% | 40,836 | +2.7% | 0.91% | +0.9% |
| Q3 2021 | $12,110,000 | +19.8% | 39,779 | +5.6% | 0.90% | +17.8% |
| Q2 2021 | $10,106,000 | +24.0% | 37,658 | +4.0% | 0.76% | +13.0% |
| Q1 2021 | $8,147,000 | +23.3% | 36,198 | +21.7% | 0.68% | +18.2% |
| Q4 2020 | $6,609,000 | +24.7% | 29,752 | +20.9% | 0.57% | +11.7% |
| Q3 2020 | $5,299,000 | +18.1% | 24,608 | -3.0% | 0.51% | +15.0% |
| Q2 2020 | $4,487,000 | +53.0% | 25,377 | +19.7% | 0.45% | +21.5% |
| Q1 2020 | $2,933,000 | +27.6% | 21,192 | +41.5% | 0.37% | +59.6% |
| Q4 2019 | $2,299,000 | +198.6% | 14,979 | +181.0% | 0.23% | +184.0% |
| Q3 2019 | $770,000 | – | 5,331 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |